News | July 23, 2025
Lonza reports 19% growth in sales in H1
Upgrades 2025 full-year CDMO sales and margin outlook
Upgrades 2025 full-year CDMO sales and margin outlook
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
The new Zigly center features and offers comprehensive veterinary services
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
Capricor’s BLA for Deramiocel received Priority Review in March 2025
The company’s largest center for medical device applications, serving the entire Asian market
Subscribe To Our Newsletter & Stay Updated
